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β-thalassemias are a group of genetic disorders characterized by reduced levels of functional 
hemoglobin (Hb).1 The prognosis of patients with β-thalassemia has improved markedly in 
recent years owing to the availability of red blood cell (RBC) transfusion and iron chelation 
therapy (ICT). Survival of patients who have been regularly transfused and treated with 
appropriate ICT now extends beyond 40 years of age.2  
Despite important improvements in patient survival, the burden of regular therapy poses a 
negative impact on patients’ quality of life (QoL). Patients with β-thalassemia who require 
regular and lifelong RBC transfusions to treat the disease are generally categorized as having 
transfusion-dependent thalassemia (TDT); non-transfusion-dependent thalassemia (NTDT) 
patients may only require occasional transfusions. Regular transfusions and associated 
complications including iron overload have a significant impact on the QoL of adult TDT 
patients.3 NTDT patients also experience significant impacts on their QoL due to their disease, 
often associated with iron overload and the difficulty of adhering to ICT.4 
As a result, health-related QoL has emerged as a key focus of comprehensive clinical care in 
patients with β-thalassemia. Understanding the degree of patient-perceived health impairment is 
essential to determine the burden of illness of β-thalassemia and to recommend suitable 
therapy. The objective of this study was to document the burden of illness (defined as 
impairment of QoL) in NTDT and TDT patients receiving standard of care with a focus on 
patient-reported physical and mental health QoL domains. 
A multisite, prospective, non-interventional observational study of adult patients with β-
thalassemia was conducted at 5 treatment centers in 4 countries: Greece (1), Italy (1), Lebanon 
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(1), and Thailand (2). Eligible patients were aged > 18 years, could read and speak the official 
local language, had a diagnosis of β-thalassemia or Hb E/β-thalassemia and Eastern 
Cooperative Oncology Group performance status score of 0 to 1, and were willing to give 
informed consent to provide self-reported QoL measurements. Patients were divided into 2 
cohorts according to their level of transfusion dependence during the 24 weeks prior to study 
entry. Participants who received ≥ 6 RBC units and had no transfusion-free period for ≥ 35 days 
were classified as having TDT. Participants who received ≤ 5 RBC units were classified as 
having NTDT. For the NTDT cohort, participants were included if their most recent Hb level was 
≤ 10 g/dL. QoL outcomes were collected using 2 validated PRO instruments, the 36-Item Short 
Form Survey version 2.0 (SF-36v2) and the Functional Assessment of Cancer Therapy-Anemia 
(FACT-An) questionnaires. Data were collected at baseline and then once every 3 weeks for up 
to 24 weeks (up to 9 time points). The primary endpoints were the 2 summary scores of the SF-
36v2, the Physical Component Score and Mental Component Score, for all patients with β-
thalassemia over the study period compared with the general population. Secondary endpoints 
included changes in SF-36v2 and FACT-An scores between TDT and NTDT patients over the 
study period. Additional details regarding the methods used can be found online in the 
Supporting Information section. 
A total of 102 patients with β-thalassemia were screened. Among them, 99 patients (TDT, n = 
49 [49.5%] and NTDT, n = 50 [50.5%]) were eligible and participated in the study between 
March 2016 and January 2017. Baseline measurements were completed for all patients except 
2 TDT patients who did not complete the SF-36v2 and FACT-An questionnaires at baseline. At 
24 weeks, collection of QoL outcomes was completed for 36 NTDT and 17 TDT patients. 
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The mean age of all patients with β-thalassemia was 31.6 years (standard deviation [SD], 10.4) 
and 69 (69.7%) patients were female (Supporting Information Table 1). The mean (SD) time 
since initial diagnosis was 24.8 years (11.4); this was longer for TDT than for NTDT patients 
(28.0 [10.4] vs 21.8 [11.5] years). At screening, mean (SD) Hb level was 8.2 g/dL (1.2) in NTDT 
patients and 8.8 g/dL (1.5) in TDT patients. Overall, 52.5% of patients had a history of clinically 
significant iron overload; this was more common in TDT patients compared with NTDT patients 
(75.5 vs 30.0%). Consequently, ICT at baseline was used more frequently in TDT patients 
(85.7%) compared with NTDT patients (24.0%). 
At baseline, mean SF-36v2 General Health score was lower for patients with β-thalassemia than 
for the general population (T-scores < 47), indicating worse QoL (Supporting Information Table 
2). Mean SF-36v2 scores for NTDT patients were lower for all domains and summary scores 
than for TDT patients, except for Role-Physical (Table). Mean (SD) differences between NTDT 
and TDT patients were clinically meaningful and reached, or were close to reaching the 
statistical significance level of 0.01 for the Mental Component Score (47.4 [8.4] vs 51.6 [7.2], P 
< 0.01), and the domains of General Health, (41.9 [8.2] vs 46.3 [10.0]; P = 0.018), Vitality (49.8 
[8.1] vs 54.0 [7.1]; P = 0.008), and Mental Health (47.8 [7.8] vs 51.7 [6.9]; P = 0.011). 
NTDT patients reported lower QoL scores than TDT patients on all domains of the FACT-An 
questionnaire (Table). Statistically significant differences were observed between NTDT and 
TDT patients for FACT-General (83.0 [11.3] vs 89.0 [10.7]; P = 0.009), and Functional Well-
Being (20.1 [4.2] vs 23.0 [3.9]; P < 0.001), indicating worse QoL in NTDT patients. 
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Mean and median decreases from baseline to Week 24 for patients with β-thalassemia were 
observed in the SF-36v2 Mental Health domain and the Physical Component Scores, indicating 
that QoL deteriorated over the study period (Supporting Information Table 3). Patients with β-
thalassemia experienced decreased QoL scores over the study period in 7 of the 12 FACT-An 
domains (Functional Well-Being, Social and Family Well-Being, Trial Outcome Index, FACT-An 
Total Score, FACT-General Total Score, Anemia Subscale, Fatigue Symptoms), indicating 
worse QoL at the end of the study. Mean change over 24 weeks was statistically significant for 
the Functional Well-Being domain (mean [SD] change −2.2 [4.0]; median change [Q1;Q3] −2.0 
[−5.0, 0.0]; P < 0.001) and the FACT-General Total Score (mean [SD] change −4.7 [11.8]; 
median change [Q1;Q3] −4.0 [−12.0, 3.0]; P = 0.005) (Supporting Information Table 3). 
Compared with TDT patients, NTDT patients had, in general, less favorable changes in QoL 
over the 24 weeks of the study. They experienced reductions in the SF-36v2 Role-Physical and 
Mental Health domain scores. Both component scores indicated impaired QoL, while TDT 
patients had maintained or slightly improved QoL. The difference in change from baseline to 
Week 24 in the SF-36v2 Role-Physical scores between NTDT and TDT patients was statistically 
significant (mean change [SD] −4.1 [9.2] vs 4.1 (8.4); P = 0.003 (Supporting Information Table 
4). Decreased FACT-An scores were observed in NTDT patients for the Emotional Well-Being, 
FACT-An Total Score, Anemia Subscale, Fatigue Symptoms, Fatigue Impact, Fatigue 
Experience, and Trial Outcome Index whereas TDT patients experienced a smaller 
deterioration, maintained or improved QoL in these domains. No significant differences were 
observed between the NTDT and TDT patients in terms of changes in FACT-An score from 
baseline to Week 24 (Supporting Information Table 4).  
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This study demonstrates the burden of disease for patients with β-thalassemia, and highlights 
observed differences in QoL between NTDT and TDT patients. In the routine clinical care 
setting, NTDT patients generally reported worse QoL across most domains of the SF-36v2, 
indicating that TDT patients have a higher level of functioning than NTDT patients. Clinically 
meaningful differences were observed for the SF-36v2 Mental Component Score, and General 
Health, Vitality, and Mental Health domains, and FACT-An Functional Well-Being, and the 
FACT-General Total Score. After 24 weeks of follow-up, changes from baseline in SF-36v2 
Role-Physical scores were significantly different between NTDT and TDT patients; NTDT 
patients experienced impaired QoL while TDT patients had maintained or slightly improved QoL. 
These results suggest that while NTDT patients may not require regular transfusions, they may 
experience a significant reduction in functional outcomes.  
The results of this study are generally aligned with results reported in the few published studies 
of QoL in patients with β-thalassemia. In Sobota et al. (2011), data from the Thalassemia 
Longitudinal Cohort of the Thalassemia Clinical Research Network is reported.5 In that study, 
patients with β-thalassemia in the USA and UK had lower scores on 7 out of 8 domains of the 
SF-36 compared with general population benchmarks; in our study, General Health was the 
only domain in which patients with β-thalassemia reported worse QoL than the general 
population. However, NTDT patients had greater QoL impairment compared with TDT patients. 
This is consistent with the Intercontinental Collaborative Study conducted in TDT and NTDT 
patients in Canada, Lebanon, and Iran, in which NTDT patients experienced significant 
reductions in QoL, as measured by SF-36, compared with TDT patients.6  
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In summary, critical unmet medical needs remain for NTDT patients as they experience poorer 
QoL compared with TDT patients. There is a need for new PRO instruments to accurately 
measure reductions in QoL in NTDT patients, as well as new interventions to treat these 
patients to reduce their unique burden of disease. Development of a new, validated PRO 
instrument, to assess the severity of symptoms in NTDT patients specifically is currently 
underway. 
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TABLE Mean differences in QoL scores between NTDT and TDT patients at baseline 
SF-36v2 
Domain / component scores NTDT patients 
(n = 50) 
mean (SD) 
TDT patients 
(n = 49) 
mean (SD) 
Difference between NTDT 
and TDT patients 
Mean 
difference 
(SD) 
 P value 
(t-test) 
Physical Functioning 50.2 (6.1) 51.1 (5.6) −0.9  0.446 
Role-Physical 49.8 (6.4) 48.5 (6.8) 1.3  0.323 
Bodily Pain 52.5 (9.2) 55.2 (6.8) −2.7  0.108 
General Health 41.9 (8.2) 46.3 (10.0) −4.4  0.018* 
Physical Component Score 49.7 (6.5) 50.3 (5.9) −0.6  0.632 
Vitality 49.8 (8.1) 54.0 (7.1) −4.2  0.008* 
Social Functioning 48.7 (7.7) 50.7 (6.9) −2.0  0.177 
Role-Emotional 47.7 (7.9) 50.3 (7.4) −2.6  0.092 
Mental Health 47.8 (7.8) 51.7 (6.9) −3.9  0.011* 
Mental Component Score 47.4 (8.4) 51.6 (7.2) −4.2  0.009* 
FACT-An 
Scales / domains NTD patients 
(n = 50) 
TDT 
patients 
Difference between NTDT 
and TDT patients 
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Mean (SD) (n = 49) 
Mean (SD) 
Mean 
difference 
(SD) 
 P value 
Physical Well-Being (k = 7) 23.0 (3.7) 23.9 (3.0) −0.9  0.197 
Social and Family Well-Being 
(k = 7) 
21.4 (4.3) 22.1 (4.5) −0.7  0.426 
Emotional Well-Being (k = 6) 18.6 (3.3) 19.9 (2.8) −1.4  0.030 
Functional Well-Being (k = 7) 20.1 (4.2) 23.0 (3.9) −3.0  ≤ 0.001* 
FACT-General (k = 27) 83.0 (11.3) 89.0 (10.7) −6.0  0.009* 
FACT-An Anemia Symptoms (k = 
7) 
21.7 (3.1) 22.4 (2.8) −0.7  0.224 
Fatigue Symptoms (k = 13) 38.3 (9.0) 40.8 (5.4) −2.5  0.104 
* Denotes statistical significance.  
FACT, Functional Assessment of Cancer Therapy; FACT-An, Functional Assessment of Cancer Therapy-Anemia; k, 
the number of items in a scale/domain; n, number; NTDT, non-transfusion dependent thalassemia; SD, standard 
deviation; SF-36v2, 36-Item Short Form Survey version 2; TDT, transfusion dependent thalassemia. 
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